These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 4419182)

  • 1. [Effect of ascorbic acid on stability of dihydroergotamine solutions].
    Wichliński L
    Acta Pol Pharm; 1974; 31(4):495-9. PubMed ID: 4419182
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of the ergot alkaloids dihydroergotamine, ergonovine, and ergotamine on growth of Escherichia coli O157:H7 in vitro.
    Looper ML; Edrington TS; Moubarak AS; Callaway TR; Rosenkrans CF
    Foodborne Pathog Dis; 2008 Oct; 5(5):599-604. PubMed ID: 18681792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ergotamine and dihydroergotamine enhance guanylate cyclase activity.
    Vesely DL
    Res Commun Chem Pathol Pharmacol; 1983 May; 40(2):245-54. PubMed ID: 6136069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the stability of injectable L-ascorbic acid solutions. 3. Effect of metal-complexing agents.
    Kassem MA; Kassem AA; Ammar HO
    Pharm Acta Helv; 1972; 47(2):89-97. PubMed ID: 5024147
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on the stability of injectable L-ascorbic acid solutions. I. Effect of pH, solvent, light and container.
    Kassem MA; Kassem AA; Ammar HO
    Pharm Acta Helv; 1969 Oct; 44(10):611-23. PubMed ID: 5354572
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on the stability of injectable L-ascorbic acid solutions. II. Effect of metal ions and oxygen content of solvent water.
    Kassem MA; Kassem AA; Ammar HO
    Pharm Acta Helv; 1969 Nov; 44(11):667-75. PubMed ID: 5364771
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of some factors on the stability of aqueous solutions of L-ascorbic acid].
    Kotkowski S; Gryglewska T
    Ann Acad Med Stetin; 1967; 13():127-37. PubMed ID: 5584493
    [No Abstract]   [Full Text] [Related]  

  • 8. [Studies on the stability of ascorbic acid injection. III. Study on the rate of degradation of 25% ascorbic acid injection].
    Yin GK; Guo YX; Ma BZ
    Yao Xue Xue Bao; 1982 May; 17(5):378-81. PubMed ID: 7180471
    [No Abstract]   [Full Text] [Related]  

  • 9. [L-ascorbic acid--brief review of stability and stabilization of aqueous solutions].
    Struhár M; Fecák B; Mandák M
    Cesk Farm; 1968 Jul; 17(6):306-11. PubMed ID: 4177357
    [No Abstract]   [Full Text] [Related]  

  • 10. [Data on the stability of L-ascorbic acid solutions. I. Stability of synthetic L-ascorbic acid solutions. II. Stabilization of synthetic L-ascorbic acid solutions with salts & sugars].
    FELDHEIM W; SEIDEMANN J
    Pharmazie; 1959 Feb; 14(2):80-3. PubMed ID: 13667443
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparative stability test of epinephrine, isoprenaline, physostigmine, promethazine and ascorbic acid solutions].
    Raether G; Jensch HP; Katzorke D; Wollmann H
    Pharmazie; 1988 Feb; 43(2):132-3. PubMed ID: 3393582
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunoassay of ergotamine and dihydroergotamine using a common 3H-labelled ligand as tracer for specific antibody and means to overcome experienced pitfalls.
    Rosenthaler J; Munzer H; Voges R; Andres H; Gull P; Bolliger G
    Int J Nucl Med Biol; 1984; 11(1):85-9. PubMed ID: 6735611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cysteine stability in aqueous amino acid solutions].
    Nekliudov AD; Verem'ëv IV
    Prikl Biokhim Mikrobiol; 1984; 20(3):387-92. PubMed ID: 6431404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology of ergotamine and dihydroergotamine.
    Silberstein SD
    Headache; 1997; 37 Suppl 1():S15-25. PubMed ID: 9009470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Improper equalization of sumatriptan with ergotamine and dihydroergotamine in the Drug Equivalency System].
    Ferrari MD; Haan J; Bax WA; van Coevorden RS; Timmerman H; Meijler WJ
    Ned Tijdschr Geneeskd; 1993 Apr; 137(17):846-50. PubMed ID: 8387648
    [No Abstract]   [Full Text] [Related]  

  • 18. [Unjustified equalization of sumatriptan with ergotamine and dihydroergotamine in the Drug Equivalency System].
    Van Mil JW
    Ned Tijdschr Geneeskd; 1993 Jun; 137(24):1213-4. PubMed ID: 8391659
    [No Abstract]   [Full Text] [Related]  

  • 19. [Studies on the stability of ergotamine solutions for injections].
    Kurchenko IN; Konev FA
    Farm Zh; 1965; 20(5):13-6. PubMed ID: 5888680
    [No Abstract]   [Full Text] [Related]  

  • 20. [Data on the stability of L-ascorbic acid solutions. I. Stability of synthetic L-ascorbic acid solutions].
    FELDHEIM W; SEIDEMANN J
    Pharmazie; 1959 Jan; 14(1):12-9. PubMed ID: 13657672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.